key: cord-0689882-4h7zaf3l
authors: Nieuwenhuijs-Moeke, Gertrude J.; Jainandunsing, Jayant S.; Struys, Michel M.R.F.
title: Sevoflurane, a sigh of relief in COVID-19?
date: 2020-05-01
journal: Br J Anaesth
DOI: 10.1016/j.bja.2020.04.076
sha: 19e8ef6703d8d87ba19889a14f2408d21f243646
doc_id: 689882
cord_uid: 4h7zaf3l

nan

Currently coronavirus disease 2019 (COVID-19) is holding the world in its grip. Numbers of infected individuals continue to increase each day and worldwide mortality rate attributable to COVID-19 is estimated as 6.8%. 1 The primary cause of death is respiratory failure as a result of acute respiratory distress syndrome (ARDS). Treatment is mainly supportive with a high failure rate, and effective preventive and treatment strategies are needed.

ARDS is characterised by injury to epithelial and endothelial cells, which triggers the innate and subsequently the adaptive immune system, and leads to an inflammatory cascade of cytokines and altered permeability of the alveolar capillary membrane. This results in an increase in alveolar oedema, interstitial oedema, or both, and the development of a systemic inflammatory response. 2 Mehta and colleagues 3 highlight the similarity of patients with a fulminant COVID-19 associated with ARDS and death with the secondary haemophagocytic lymphohistiocytosis syndrome. This hyperinflammatory syndrome is characterised by hypercytokinaemia ('cytokine storm') and multiple organ failure. The cytokine profile is characterised by increased interleukin-2, interleukin-7, granulocyte colony stimulating factor, interferon-g inducible protein 10, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-a, and tumour necrosis factor-a (TNF-a). Mehta and colleagues 3 suggest that this group of patients could benefit from immunosuppressive strategies, and several agents targeting innate and adaptive immune responses (chloroquine, methylprednisolone, tacrolimus, tocilizumab, sarilumab, bevacizumab) are being tested (NCT04324463, NCT04317092, NCT04315298, NCT04341038, NCT04275414).

Another adjunct treatment that might be of some benefit in COVID-19 is inhalation of volatile anaesthetics. Because of the rapid increase of infected individuals with severe ARDS requiring emergent medical treatment and mechanical ventilation, ICUs all over the world have been flooded with patients, exhausting critical care resources. These patients require sedation, most frequently using the i.v. sedative midazolam or anaesthetic propofol, together with an opioid and neuromuscular blocking agent. Shortages of these drugs are occurring, and alternative drug options must be considered. A low-cost alternative sedation strategy could be the use of volatile anaesthetic agents such as sevoflurane. Volatile anaesthetics are associated with faster onset and offset, fewer hallucinations, and reduced opioid needs compared with i.v. sedatives. Use of volatile anaesthetics for sedation in ICU patients is increasingly being considered. In Germany, the DAS taskforce 2015 proposes the use of volatile anaesthetics for moderate-to-deep sedation as an option in their 'evidenceand consensus-based guidelines on the management of analgesia, sedation, and delirium in intensive care'. 4

Several trials have evaluated the safety of long-term sedation with volatile anaesthetics in the ICU, with durations reported between 1 and 12 days and end-tidal concentrations of 0.5 vol % and 0.5e1.0 vol% for isoflurane and sevoflurane, respectively. 5e7 A retrospective analysis of 200 critically ill surgical patients admitted to the ICU reported reduced inhospital mortality (odds ratio 0.35; 95% confidence interval 0.18e0.68) and 1-yr mortality (odds ratio 0.41; 95% confidence interval 0.21e0.81) in patients sedated with isoflurane compared with propofol-midazolam. 6 A limitation of this analysis was the potential of selection bias. In an RCT, sedation with sevoflurane (0.5 vol%) for a mean of 50 h resulted in improved haemodynamic stability, improved awakening quality score, and reduced opioid consumption compared with propofol or midazolam sedation. 7 Mean plasma fluoride concentration was 82 mM (12e220 mM). Although this is above the nephrotoxic threshold of 50 mM, no renal or hepatic injury was reported. 7, 8 This threshold of 50 mM is based on clinical experiments with methoxyflurane that showed a dose-related correlation between inorganic fluoride (a metabolite of all halogenated volatile anaesthetics) concentration and renal dysfunction. 8 Subsequently, this threshold was applied to other volatile anaesthetics, although higher fluoride concentrations have been measured in the case of sevoflurane without clinical signs of renal injury. 9,10 Polyuria and nephrogenic diabetes insipidus (NDI) have been observed after long-term sedation with volatile anaesthetics. Cabibel and colleagues 11 reported three cases in which development of NDI was associated with prolonged (4, 6, and 13 days) sedation with sevoflurane (1.0 vol%). In a retrospective study, L'Heud e and colleagues 12 analysed ICU patients who developed NDI and were exposed to longer duration ( 

Various publications report on the administration of volatile anaesthetics with conventional ICU ventilators using specific administration devices such as AnaConDa® (Sedana Medical, Danderyd, Sweden) and Mirus® (Pall Medical, Dreieich, Germany). 13 During this COVID-19 pandemic, many hospitals were forced to use anaesthesia ventilators in the ICU with the possibility to administer volatile anaesthetics without the need of these specific devices. Institutions using anaesthesia ventilators in the ICU should be aware that use of these ventilators in the ICU is off-label and a risk-benefit assessment should be carefully made by the responsible healthcare professionals. Clinical teams should be trained to understand the specific features of these devices and fundamental differences between anaesthesia and conventional ICU ventilators. More specifically, when using anaesthesia ventilators at the ICU to administer volatile anaesthetics for a longer period of time, consideration of the fresh gas flow is important. In contrast to the use of low or minimal fresh gas flows in the operating theatre when administering volatile anaesthetics in an attempt to minimise environmental effects and costs, 14 higher fresh gas flows might be required when using anaesthesia ventilators in the ICU to avoid rapid exhaustion of carbon dioxide absorbers, water traps, excessive standing water in the breathing circuit, and condensation in filters and valves compromising the ventilator functionality. Various solutions including active charcoal filters and alternative scavenging systems have been proposed to avoid air pollution by volatile anaesthetics in the ICU. 15 

Volatile anaesthetics have immune modulating properties either by direct effects on immune cells or indirect effects on cellular protective pathways in endothelial or epithelial cells that reduce death signals and the subsequent inflammatory response. 16 Protective effects of volatile anaesthetics have been shown in ischaemia and reperfusion injury in various organs, and increasing evidence indicates protective roles of volatile anaesthetics in sepsis and ARDS. In a sepsis model of caecal ligation and puncture, mice treated with a volatile anaesthetic showed improved overall survival and reduced 7day mortality, with the greatest effect exerted by sevoflurane. 17 Alanine transaminase and aspartate transaminase concentrations were lower in the sevoflurane-treated group, as were concentrations of interleukin-6 and MCP-1. 17 In a lipopolysaccharide-induced sepsis model in rats, concentrations of MCP-1, interleukin-6, and cytokine-induced neutrophil chemoattractant protein-1 measured 3, 6, and 12 h after lipopolysaccharide infusion were lower in sevoflurane-treated rats compared with propofol-treated rats. 18 Koutsogiannaki and colleagues 19 showed that improved survival in sevoflurane-treated mice subjected to sepsis was associated with less apoptosis in the spleen. Sevoflurane reduced neutrophil apoptosis by a Fas death domain-Fas-associated death domain interaction.

Several trials have addressed the potential benefits of volatile anaesthetics in animals and patients with ARDS. In a porcine model of ARDS, sevoflurane improved Pa o2 =Fi o2 ratio 4 h after administration compared with propofol. Concentrations of interleukin-1b, interleukin-6, and TNF-a in bronchoalveolar lavage were lower in the sevoflurane group, as was the polymorphonuclear neutrophil count. 2 Reduced permeability of the alveolar capillary membrane and lower extravascular lung water index was seen in the sevofluranetreated pigs. In a clinical trial, Jabaudon and colleagues 20 compared the effect of sevoflurane sedation with midazolam sedation in ARDS patients. Treatment with sevoflurane improved the Pa o2 =Fi o2 ratio and reduced concentrations of interleukin-6 and TNF-a in sevofluranetreated patients.

MacDonald and colleagues 21 reported that the use of halogenated volatile anaesthetics in mice was accompanied by modulation of the type 1 interferon response to influenza, and that volatile anaesthetic exposure resulted in decreased bacterial burden, improved clinical score, and reduced lung injury. Against viral infections such as the measles, volatile anaesthetics have proved to be able to decrease viral load. 22e24 Volatile anaesthetics also exhibit antibacterial properties against Streptococcus pneumoniae and Haemophilus influenzae, providing some protection against bacterial superinfection in the setting of viral inflammation. 25 

The current situation makes it feasible to investigate the potential beneficial effects of volatile anaesthetics on systemic inflammation, sepsis, and ARDS in mechanically ventilated COVID-19 patients, while at the same time augmenting the range of sedative drugs in this still increasing ICU population. We advocate seizing this exceptional opportunity to study this hypothesis worldwide. It is imperative that well-designed dose finding trials or RCTs are conducted according to the guidelines of good clinical practice, both for the drug itself and for the medical devices applied to administer the drug in the ICU. 

MMRFS is a director of the British Journal of Anaesthesia. The other authors declare that they have no conflicts of interest.

WHO. Coronavirus disease 2019 (COVID-19) situation report-93

Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study

COVID-19: consider cytokine storm syndromes and immunosuppression

Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine. Revision 2015 (DAS-Guideline 2015) -short version

Halogenated volatile anesthetics in the intensive care unit: current knowledge on an upcoming practice

Survival after long-term isoflurane sedation as opposed to intravenous sedation in critically ill surgical patients: retrospective analysis

Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam

Methoxyflurane nephrotoxicity. A study of dose response in man

Renal function in patients with high serum fluoride concentrations after prolonged sevoflurane anesthesia

Renal integrity in sevoflurane sedation in the intensive care unit with the anesthetic-conserving device: a comparison with intravenous propofol sedation

Complete nephrogenic diabetes insipidus after prolonged sevoflurane sedation: a case report of 3 cases

Nephrogenic diabetes insipidus associated with prolonged sedation with sevoflurane in the intensive care unit

AnaConDa™ and Mirus™ for intensive care sedation, 24 h desflurane versus isoflurane in one patient

Inhalation anaesthetics and climate change

State of the art: sedation concepts with volatile anesthetics in critically Ill patients

Immune modulation by volatile anesthetics

Volatile anesthetics improve survival after cecal ligation and puncture

Sevoflurane attenuates systemic inflammation compared with propofol, but does not modulate neuroinflammation: a laboratory rat study

The volatile anesthetic sevoflurane reduces neutrophil apoptosis via Fas death domain-Fas-associated death domain interaction

Sevoflurane for sedation in acute respiratory distress syndrome. A randomized controlled pilot study

Halothane modulates the type i interferon response to influenza and minimizes the risk of secondary bacterial pneumonia through maintenance of neutrophil recruitment in an animal model

Anesthetic action and virus replication: inhibition of measles virus replication in cells exposed to halothane

Inhibiting effects of enflurane and isoflurane anesthesia on measles virus replication: comparison with halothane

Effect of halothane on the replication of animal viruses

The effect of volatile anaesthetics on common respiratory pathogens. Halothane, trichloroethylene and methoxyflurane